The Carter Center, Atlanta, Georgia.
The Carter Center, Jos, Nigeria.
Am J Trop Med Hyg. 2024 Apr 9;111(3_Suppl):69-80. doi: 10.4269/ajtmh.23-0600. Print 2024 Sep 3.
In Nigeria, mass drug administration (MDA) for schistosomiasis (SCH) and soil-transmitted helminthiasis (STH) has often been coordinated with other programs that receive greater external funding. As these programs reach stop MDA milestones, SCH and STH programs will likely need to transition implementation, or "mainstream," to domestic support. A mixed-methods study was conducted in four districts before (2021) and after (2022) mainstreaming to evaluate its impact on MDA coverage. Household surveys were done in 30 villages per district pre- and post-mainstreaming. All selected communities were eligible for STH treatment; around a third were eligible for SCH treatment. Mass drug administration was primarily conducted in schools. A total of 5,441 school-aged children were included in pre-mainstreaming and 5,789 were included in post-mainstreaming. Mass drug administration coverage was heterogeneous, but overall, mebendazole coverage declined nonsignificantly from 81% pre-mainstreaming to 76% post-mainstreaming (P = 0.09); praziquantel coverage declined significantly from 73% to 55% (P = 0.008). Coverage was significantly lower among unenrolled children or those reporting poor school attendance in nearly every survey. For the qualitative component, 173 interviews and 74 focus groups were conducted with diverse stakeholders. Respondents were deeply pessimistic about the future of MDA after mainstreaming and strongly supported a gradual transition to full government ownership. Participants formulated recommendations for effective mainstreaming: clear budget allocation by governments, robust and targeted training, trust building, and comprehensive advocacy. Although participants lacked confidence that SCH and STH programs could be sustained after reductions in external support, initial results indicate that MDA coverage can remain high 1 year into mainstreaming.
在尼日利亚,大规模药物治疗(MDA)用于治疗血吸虫病(SCH)和土壤传播性蠕虫病(STH)通常与其他获得更多外部资金的项目协调进行。随着这些项目达到停止 MDA 的里程碑,SCH 和 STH 项目可能需要过渡实施,即“主流化”,以获得国内支持。在主流化之前(2021 年)和之后(2022 年),在四个地区进行了一项混合方法研究,以评估其对 MDA 覆盖率的影响。在主流化之前和之后,每个地区都进行了 30 个村庄的家庭调查。所有选定的社区都有资格接受 STH 治疗;大约三分之一有资格接受 SCH 治疗。大规模药物治疗主要在学校进行。共有 5441 名学龄儿童在主流化前和 5789 名学龄儿童在主流化后被纳入研究。大规模药物治疗的覆盖范围存在差异,但总体而言,阿苯达唑的覆盖率从主流化前的 81%略有下降到主流化后的 76%(P = 0.09);吡喹酮的覆盖率从 73%显著下降到 55%(P = 0.008)。在几乎每一次调查中,未入学儿童或报告出勤率低的儿童的覆盖率都显著较低。在定性部分,与不同利益相关者进行了 173 次访谈和 74 次焦点小组讨论。受访者对主流化后 MDA 的未来深感悲观,并强烈支持逐步过渡到完全由政府拥有。参与者为有效的主流化提出了建议:政府明确分配预算、强有力和有针对性的培训、建立信任以及全面宣传。尽管参与者对减少外部支持后 SCH 和 STH 项目能否持续表示缺乏信心,但初步结果表明,MDA 覆盖率在主流化后 1 年内仍保持较高水平。